Tag Archive for: Lineagen

Heather Creran Joins Lineagen as Chief Operating Officer (CEO)

Life Science Partner has recruited Heather Creran to become the Chief Operating Officer for Lineagen, an innovative genetics diagnostics company for neurodevelopmental disorders.

Creran’s depth of operational leadership experience will be a great asset for Lineagen, whose painless cheek swab test can detect hundreds of genetic conditions which can give rise to developmental delay and autism spectrum disorder. Lineagen’s test results are customized to help patients, parents and providers fully understand diagnoses and develop a healthcare management program which is tailored to the individual patient’s needs.

Heather Creran

“Throughout her career, Creran has demonstrated a knack for strategic thinking and operational success,” emphasized Tom Callaway, President and Founder of Life Science Partner. Creran comes to Lineagen with extensive experience in highly relevant leadership roles. Most recently, she served as President and Board Director for Emory Genetics Laboratory, a joint venture between Emory University and the US Clinical Diagnostics Division of Eurofins Scientific, an international provider of bioanalytical testing and genomics services. Also of note is Creran’s experience as President and CEO of the cancer diagnostics company SCI Laboratories.

Creran looks forward to leveraging her passion for operational excellence to pursue accelerating growth and success at Lineagen.

About Life Science Partner Executive Search

Life Science Partner is a specialized executive search firm that recruits transformational leaders for healthcare and life sciences companies. Our high-touch, partner-led process ensures an exceptional level of service, while our backgrounds as physicians and industry executives enable us to efficiently deliver the brightest candidates in the medical device, biopharmaceuticals, diagnostics, and healthcare technology fields.

Learn More About Chief Executive Functions
/0 Comments/by

Francis Ota, MBA, Joins Lineagen as Chief Financial Officer

Former Executive Vice President, Finance MDxHealth

Life Science Partner recruited Francis Ota to become the Chief Financial Officer at Lineagen, an innovative genetics diagnostics company for neurodevelopmental disorders. Ota joins Lineagen after serving as the Executive Vice President of Finance for MDxHealth, a publically owned Belgium based diagnostic company with a US CLIA lab that develops epigenetic tests for cancer assessments.

During his tenure at MDxHealth, Ota played a key role in generating profitable growth, raising capital and negotiating M&A transactions. Earlier in his career he held financial leadership roles at Focus Diagnostics (acquired by Quest), QUAD Research, and Medtronic among others.

“As a global leader in finance, Ota has overseen the financial management of a CLIA laboratory from rapid growth through exit via acquisition,” states Tom Callaway, MD, President of Life Science Partner. “With his solid understanding of the reimbursement and revenue management challenges of a CLIA lab, Ota will serve as a critical member of Lineagen’s leadership team.”

Ota earned his Bachelor of Science Degree in Finance and International Business from the University of Colorado and his MBA from the University of California.

/0 Comments/by

Bob Wassman, MD, Recruited to become Chief Medical Officer for Lineagen

Former Chief Medical Officer Rosetta Genomics

Life Science Partner recruited Bob Wassman, MD, to become Chief Medical Officer of Lineagen to lead The Company’s clinical direction, product strategy, medical affairs, and global trials and registration process for Lineagen’s products and services.

Previously, as Chief Medical Officer for Rosetta Genomics, Wassman played a critical role in building the commercial, clinical and reimbursement strategy for the Rosetta’s microRNA-based platform technologies. He partnered closely with CEO Ken Berlin to evaluate new technologies to build out a fully personalized medicine resulting in the acquisition of PersonalizedDx.

Wassman joined Rosetta after leading the pharmagenomics services program at CVS Caremark, after, It’s acquisition of Generation Health, to improve precision therapy management and guide program development. Throughout his career Wassman has served in several key genomic leadership roles for cutting edge companies such as Good Start Genetics, Celula, Genzyme, and Prometheus.

“With a successful track record in building CLIA-based laboratory businesses combining scientific and clinical knowledge, Wassman will be a critical asset for Lineagen’s future growth and development,” stated Tom Callaway, MD, President and Founder of Life Science Partner.

Wassman earned a Bachelor of Science Degree in Biology from Yale University and his MD from Albany Medical College.

Learn More About Chief Medical or Regulatory Leaders
/0 Comments/by